Morepen Laboratories Ltd. NSE: MOREPENLAB | BSE: 500288

Mid-range Performer

Download real time

62.67 -0.80 (-1.26%)

37.89% Fall from 52W High

2.2M

NSE+BSE Volume

NSE 11 Jul, 2025 3:31 PM (IST)

Morepen Laboratories Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Morepen Laboratories Ltd. from all sources in a single place.

Load latest

Morepen Laboratories Ltd.

28 Apr 2025

62.67

-1.26%

Company Update

Morepen Laboratories Ltd - 500288 - Intimation Of Formation Of A Wholly Owned Subsidiary In Dubai, …

BSE India

Please find attached the file

Morepen Laboratories Ltd.

24 Apr 2025

62.67

-1.26%

Morepen stock soars over 14% on growth plans

Business Line

Morepen Laboratories said its 325-crore formulation business was targeting 1,000 crore in five years, on the back of local and global sales

Morepen Laboratories Ltd. is trading below its 30 day SMA of 63.5

Morepen Laboratories Ltd.

24 Apr 2025

62.67

-1.26%

Company Update

Morepen Laboratories Ltd - 500288 - Launch Of Four New Products

BSE India

File Attached

Morepen Laboratories Ltd.

19 Apr 2025

62.67

-1.26%

Morepen Labs Targets Rs 5,000 Crore Revenue By FY30

NDTV Profit

Morepen Labs aims for a 15% to 16% Ebitda margin over the next five years, and could achieve a margin of 20% in the longer run, its CMD suggested.

Morepen Laboratories Ltd. is trading below its 30 day SMA of 63.5

Morepen Laboratories Ltd.

17 Apr 2025

62.67

-1.26%

Company Update

Morepen Laboratories Ltd - 500288 - Intimation Of Name Change Of Subsidiary Company

BSE India

The Name of Morepen Medtech Limited, subsidiary company has been changed to Morepen Medipath Limited.

Morepen Laboratories Ltd.

11 Apr 2025, 12:07PM

62.67

-1.26%

Morepen to hire 1,000 medical representatives to boost formulations biz

Business Standard

Morepen Laboratories on Friday said it will add more than 1,000 medical representatives over the next three years, with over 200 team members expected to join in FY26 alone. The company aims to strengthen its formulations business in the market through new hirings. "This expansion represents a pivotal moment in Morepen's journey as we sharpen our focus on the expanding domestic finished dosage market," Morepen Laboratories Chairman and MD Sushil Suri said in a statement. With significant increase in the sales force and enhanced reach to doctors, pharmacies, and patients, the drugmaker is setting the stage for getting a bigger pie in the Indian pharmaceutical market valued at Rs 2.38 lakh crore, yielding higher gross margins and better returns for stakeholders in the long run, he added. Currently, Morepen's formulation business stands around Rs 325 crore, and the company is targeting to touch Rs 1,000 crore in the next five years. This goal will be supported by an aggressive expans

Morepen Laboratories Ltd. is trading below its 30 day SMA of 63.5

Morepen Laboratories Ltd.

11 Apr 2025, 08:57AM

62.67

-1.26%

Company Update

Morepen Laboratories Ltd - 500288 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Please find enclosed press release.

Morepen Laboratories Ltd.

01 Apr 2025

62.67

-1.26%

Morepen Labs rises 4% after China approves anti-allergy API export

Business Standard

The company commands an over 80 per cent market share in the US generics market for Loratadine, according to its filing

Morepen Laboratories Ltd.'s price crossed below 50Day SMA today

Morepen Laboratories secures approval for Loratadine API in China

Business Line | 01 Apr 2025

Morepen Laboratories Ltd.

01 Apr 2025

62.67

-1.26%

Company Update

Morepen Laboratories Ltd - 500288 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Please find enclosed press release titled Morepen secured Loratadine approval for export to China.

Morepen Laboratories Ltd.

01 Apr 2025

62.67

-1.26%

Company Update

Morepen Laboratories Ltd - 500288 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Please find enclosed press release titled Morepen secured Loratadine approval for export to China.

Is Morepen Laboratories Ltd. worth buying?

765 Votes:

Buy 81.96%

Sell 8.1%

Hold 9.93%